Last update: May 13, 2019

Лаурет 4

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

A mixture of macrogol ethers. An anionic surfactant detergent with sclerosing properties on varicose veins.
Administration by local injections in the vein to be sclerosed.
It contains 5% alcohol.

Since the last update we have not found any published data on its excretion in breast milk.

After local injections, low plasma levels have been detected in some patients (FDA 2010). Its moderately high molecular weight, large volume of distribution and short half-life (AEMPS 2017, FDA 2010) would hinder transfer into breastmilk.

Several experts believe that the use of this medication is probably compatible during breastfeeding (Briggs 2017, Hale 2017 p784).

Due to the lack of accurate pharmacokinetic data and given that after 5 half-lives of elimination (5 T½), 97% of a substance is eliminated from the body (Anderson 2016), it may be prudent, in order to minimize any possible exposure, to stop breastfeeding between 7 - 8 hours after the last sclerosing injection. However, the manufacturer advises a waiting period of 2 to 3 days (AEMPS 2017) which seems excessive since it is not based on the pharmacokinetics of the product.


See below the information of this related product:

Alternatives

We do not have alternatives for Лаурет 4.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Pharmacokinetics

Variable Value Unit
Molecular weight 583 (400 - 600) daltons
VD 0,26 - 1,2 l/Kg
pKa 6,5 -
T1/2 0,9 - 1,5 hours

References

  1. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. 11th edition (acces on line) 2017
  2. Hale TW, Rowe HE. Medications & Mothers' Milk. A Manual of Lactation Pharmacology. Springer Publishing Company. 2017
  3. AEMPS-CFK&Co. Lauromacrogol(Etoxisclerol). Ficha técnica. 2017 Full text (in our servers)
  4. Anderson PO. Cancer Chemotherapy. Breastfeed Med. 2016 May;11:164-5. Abstract Full text (link to original source) Full text (in our servers)
  5. FDA-CFKCo Polidocanol (Asclera). Drug Summary. 2010 Full text (in our servers)

Total visits

111

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM